9966 — Alphamab Oncology Cashflow Statement
0.000.00%
Last trade - 00:00- HK$8.76bn
- HK$7.36bn
- CNY566.24m
Annual cashflow statement for Alphamab Oncology, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | — |
| Source: | ARS | ARS | ARS | ARS | |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | fx Preliminary |
| Net Income/Starting Line | -412 | -326 | -211 | 166 | — |
| Depreciation | |||||
| Non-Cash Items | 13.3 | -69.3 | -69.4 | -44.2 | — |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 37.4 | 39.5 | 8.01 | 13.1 | — |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -321 | -300 | -203 | 212 | — |
| Capital Expenditures | -158 | -130 | -36.2 | -21.8 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 732 | 980 | 18.1 | -71.2 | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 574 | 851 | -18.1 | -92.9 | — |
| Financing Cash Flow Items | -14.9 | -19.3 | -15.1 | -9.23 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 364 | -311 | 218 | -99 | — |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 618 | 266 | 16.8 | 26.1 | — |